NanoViricides Advances Phase 2 Trials for Broad-Spectrum Antiviral NV-378 in $17B Market
ByAinvest
Wednesday, Dec 17, 2025 10:30 am ET1min read
NNVC--
NanoViricides is advancing Phase 2 trials for its broad-spectrum antiviral NV-378, targeting multiple viral threats, including Mpox, influenza, COVID-19, and RSV. Analysts at Alliance Global Partners estimate a $17B market opportunity for the company's pipeline and value NV-378 for Mpox at $5.25 per share, supporting a $6 price target. The nanoviricide platform is designed to bind, engulf, and destroy viruses without relying on the host immune system, offering potential treatment options for patients with weakened immunity.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet